Publications by authors named "S Skates"
Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Methods: In UKCTOCS between Apr-2001 and Sep-2005, 101,314 postmenopausal women were randomised to no screening (NS) and 50,625 to annual multimodal screening (MMS) (until Dec-2011) using serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA).
Article Synopsis
- Annual low-dose CT scans can detect early-stage lung tumors in smokers and lower cancer death rates by 20%, but many eligible patients don’t get screened.
- Mazzone and his team have developed a blood test that analyzes cfDNA to identify individuals who might benefit from further CT imaging.
- This pre-screening approach aims to improve screening rates and focus resources on those at higher risk for lung cancer.
Purpose: Sybil is a validated publicly available deep learning-based algorithm that can accurately predict lung cancer risk from a single low-dose computed tomography (LDCT) scan. We aimed to study the effect of image reconstruction parameters and CT scanner manufacturer on Sybil's performance.
Materials And Methods: Using LDCTs of a subset of the National Lung Screening Trial participants, which we previously used for internal validation of the Sybil algorithm (test set), we ran the Sybil algorithm on LDCT series pairs matched on kilovoltage peak, milliampere-seconds, reconstruction interval, reconstruction diameter, and either reconstruction filter or axial slice thickness.
Article Synopsis
- - The Mercy Halo Ovarian Cancer Test (OC Test) is a new screening method that detects ovarian cancer by analyzing proteins found on tumor-associated extracellular vesicles in blood, aiming for both high sensitivity and specificity.
- - In a study involving 397 women, the OC Test showed impressive results: 97% specificity and sensitivity for high-grade serous carcinoma (HGSC), and it also identified 73.5% of non-HGSC ovarian cancer cases.
- - Compared to the conventional cancer antigen 125, the OC Test resulted in fewer false positives among patients with non-cancerous conditions, indicating its potential for effective ovarian cancer screening.
Background: Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival. Thus, it is essential to continue developing and validating new treatment strategies and markers to identify patients who would benefit from the new strategy.
View Article and Find Full Text PDF